OHDSI MEETINGS THIS WEEK
OHDSI Community Call - Tuesday at 12pm EThttps://meetings.webex.com/collabs/#/meetings/detail?uuid=M59X2V1U61WC9ASID2Z5N3UT95-D1JL&rnd=811649.9868221
Population-Level Estimation (Eastern hemisphere) workgroup meeting - Wednesday at 3pm Hong Kong timehttps://meetings.webex.com/collabs/meetings/join?uuid=M6WE9AOKFETH2VEFPVCZWWBIT0-D1JL
Architecture Working Group - Thursday at 10am EThttps://jjconferencing.webex.com/jjconferencing/j.php?MTID=m3e1ceeca56f1e94c9fcf1ae98c10e02e
GIS working group meeting - Next Monday (February 12th) at 10am ET
Simple, modern video meetings for the global workforce. Join from anywhere, including your desktop, browser, mobile device, or video room device.
CDM and Vocabulary WG - Next Tuesday (February 13th) at 1pm ET
ANNOUNCEMENTS
Health Data Stories: February is American Heart Month. What research questions can the OHDSI community tackle in support of heart health? Let Patrick know here: February is American Heart Month: What can OHDSI do to help the cause? January is Thyroid Awareness Month: What health data stories do you have to share?
2018 OHDSI Symposium - SAVE THE DATE!
2018 OHDSI F2F: Registration will open soon for the next OHDSI face-to-face will take place on May 2-3rd 2018 at Columbia University Medical Center in New York. Watch the forum for updates.
Sometimes, what you’re looking for is already there.
COMMUNITY PUBLICATIONS
Adaptive MCMC for multi-partite data in Bayesian Phylogeneticshttps://lirias.kuleuven.be/handle/123456789/611652
Estimating summary statistics for electronic health record laboratory data for use in high-throughput phenotyping algorithms.http://europepmc.org/abstract/med/29369797
Methodological variations in lagged regression for detecting physiologic drug effects
Inferring pregnancy episodes and outcomes within a network of observational databases.
A Matcho, P Ryan, D Fife, D Gifkins, C Knoll and A Friedman,
PloS one , 2018
Administrative claims and electronic health records are valuable resources for evaluating pharmaceutical effects during pregnancy. However, direct measures of gestational age are generally not available. Establishing a reliable approach to infer the duration and outcome of a pregnancy could improve pharmacovigilance activities. We developed and applied an algorithm to define pregnancy episodes in four observational databases: three US-based claims databases: Truven MarketScan® Commercial Claims and Encounters (CCAE), Truven MarketScan® Multi-state Medicaid (MDCD), and the Optum ClinFormatics® (Optum) database and one non-US database, the United Kingdom (UK) based Clinical Practice Research Datalink (CPRD). Pregnancy outcomes were classified as live births, stillbirths, abortions and ectopic pregnancies. Start dates were estimated using a derived hierarchy of available pregnancy markers, including records such as last menstrual period and nuchal ultrasound dates. Validation included clinical adjudication of 700 electronic Optum and CPRD pregnancy episode profiles to assess the operating characteristics of the algorithm, and a comparison of the algorithm's Optum pregnancy start estimates to starts based on dates of assisted conception procedures. Distributions of pregnancy outcome types were similar across all four data sources and pregnancy episode lengths found were as expected for all outcomes, excepting term lengths in episodes that used amenorrhea and urine pregnancy tests for start estimation. Validation survey results found highest agreement between reviewer chosen and algorithm operating characteristics for questions assessing pregnancy status and accuracy of outcome category with 99-100% agreement for Optum and CPRD. Outcome date agreement within seven days in either direction ranged from 95-100%, while start date agreement within seven days in either direction ranged from 90-97%. In Optum validation sensitivity analysis, a total of 73% of algorithm estimated starts for live births were in agreement with fertility procedure estimated starts within two weeks in either direction; ectopic pregnancy 77%, stillbirth 47%, and abortion 36%. An algorithm to infer live birth and ectopic pregnancy episodes and outcomes can be applied to multiple observational databases with acceptable accuracy for further epidemiologic research. Less accuracy was found for start date estimations in stillbirth and abortion outcomes in our sensitivity analysis, which may be expected given the nature of the outcomes.
Enabling Open Science for Health Research: Collaborative Informatics Environment for Learning on Health Outcomes (CIELO)
P Payne, O Lele, B Johnson and E Holve,
Journal of medical Internet research , Jul 31 2017
There is an emergent and intensive dialogue in the United States with regard to the accessibility, reproducibility, and rigor of health research. This discussion is also closely aligned with the need to identify sustainable ways to expand the national research enterprise and to generate actionable results that can be applied to improve the nation's health. The principles and practices of Open Science offer a promising path to address both goals by facilitating (1) increased transparency of data and methods, which promotes research reproducibility and rigor; and (2) cumulative efficiencies wherein research tools and the output of research are combined to accelerate the delivery of new knowledge in proximal domains, thereby resulting in greater productivity and a reduction in redundant research investments.AcademyHealth's Electronic Data Methods (EDM) Forum implemented a proof-of-concept open science platform for health research called the Collaborative Informatics Environment for Learning on Health Outcomes (CIELO).The EDM Forum conducted a user-centered design process to elucidate important and high-level requirements for creating and sustaining an open science paradigm.By implementing CIELO and engaging a variety of potential users in its public beta testing, the EDM Forum has been able to elucidate a broad range of stakeholder needs and requirements related to the use of an open science platform focused on health research in a variety of "real world" settings.Our initial design and development experience over the course of the CIELO project has provided the basis for a vigorous dialogue between stakeholder community members regarding the capabilities that will add the greatest value to an open science platform for the health research community. A number of important questions around user incentives, sustainability, and scalability will require further community dialogue and agreement.
Use of SGLT2 inhibitors for diabetes and risk of infection: Analysis using general practice records from the NPS MedicineWise MedicineInsight program.
S Gadzhanova, N Pratt and E Roughead,
Diabetes research and clinical practice , Aug 2017
To explore the feasibility of MedicineInsight data to support risk management plan evaluation, focusing on sodium glucose co-transporter 2 (SGLT2) inhibitors for type 2 diabetes.A retrospective study using de-identified electronic general practitioner records. Patients who initiated SGLT2 inhibitor between 1 Jan 2012 to 1 Sep 2015 were compared to patients who initiated dipeptidyl peptidase 4 (DPP-4) inhibitors. The two cohorts were followed-up for six months. Risk of urinary-tract (UT) and genital infections was evaluated. The indication for use of SGLT2 inhibitors, recommended prior diabetes therapies and recommended monitoring were investigates.There were 1977 people in the SGLT2 cohort (with 93% initiated on dapagliflozin) and 1964 people in the DPP-4 cohort. Of the SGLT2 initiators, 54% had a documented indication for use as type 2 diabetes; 86% had used metformin and/or a sulfonylurea in the prior 12months. Renal function monitoring was documented for only 25% in the 6months initiation. The frequency of UTI in the 6months post SGLT2 initiation was not significantly increased compared to the DPP-4 cohort (3.6%vs 4.9%; aHR=0.90, 95% CI 0.66-1.24). Genital infection were more frequent in the SGLT2 than in the DPP-4 cohort (2.9% vs 0.9%, aHR=3.50, 95% CI 1.95-5.89).Similar to existing evidence, we found a higher risk of genital infection associated with SGLT2 inhibitors (primarily dapagliflozin) but no increased risk of UTIs compared to DPP-4 use.
